Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
Status:
Completed
Trial end date:
2019-01-05
Target enrollment:
Participant gender:
Summary
This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile
of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of
0.1 mg/kg by subcutaneous (SC) injection in healthy subjects.
Phase:
Early Phase 1
Details
Lead Sponsor:
Auritec Pharmaceuticals
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)